Nosocomial Candida bloodstream infections rank among infections with highest mortality rates. A retrospective cohort analysis was conducted at Catholic University Hospital to estimate risk factors for mortality of patients with candidemia. We reviewed records for patients with a Candida bloodstream infection over a 5-year period (January 2000 through December 2004). Two hundred ninety-four patients (42.1% male; mean age ± standard deviation, 65 ± 12 years) were studied.
INTRODUCTION
4 determine whether the biofilm formation by Candida species, which is intrinsically associated with its infectiousness (3, 32) , influenced the clinical outcomes in patients with candidemia. 
A C C E P T E D
on
MATERIALS AND METHODS
Study design, patient population, and data collection. This retrospective cohort study was conducted from January 2000 to December 2004 at the Catholic University Hospital in Rome, Italy, which admits about 60,000 patients annually, with the outcome measure being mortality. Accordingly, two groups of patients (survivors and nonsurvivors) were compared.
Eligible patients who were hospitalized during the study period and had at least one positive blood culture for Candida species were identified by electronically querying the microbiology laboratory historical database. A standardized case report form was used to extract the following data from the patients' hospital records: age, sex, past medical and surgical history; Candida species type and date of culture; presence of a central venous catheter and/or indwelling urinary catheter; total parenteral nutrition administration; immunosuppressive therapy (antineoplastic agents and corticosteroids) within 30 days before infection; degree and duration of neutropenia; APACHE III score (16); type of hospital admission (medical or surgical); location of patient at time of blood culture (ICU or non-ICU), and duration of hospitalization. The type, dose, and duration of antifungal therapy were also identified.
Definitions. Candidemias were defined as hospital-acquired if patients developed positive blood cultures after 48 h of hospital admission (7). Other episodes of candidemia were classified as health-care associated or community-acquired according to definitions suggested by Friedman et al. (5) . Criteria for defining healthcare-associated candidemia include: intravenous therapy received at home; wound care or specialized nursing care through a healthcare agency, family, or friends, or self-administered intravenous medical therapy within 30 days prior to onset of candidemia; hospital or hemodialysis clinic attendance or intravenous chemotherapy received within 30 days prior to onset of candidemia; hospitalization in an acute care hospital for 2 or more days within 90 days prior to onset of candidemia; and residence in a nursing home or long-term care facility (5) .
Candidemia was defined as CVC-related if i) the semiquantitative catheter tip culture yielded more than 15 CFU of the same Candida species or ii) simultaneous quantitative cultures showed a ratio Biofilm formation assays. Biofilm formation was determined according to well-established protocols (19, 33, 37) , with slight modifications. To induce in vitro biofilm production by Candida isolates, Sabouraud dextrose broth (SDB) containing 8% glucose was used. Candida albicans ATCC 90028 and C. parapsilosis ATCC 96142 served as controls in each experiment. Testing of isolates was performed on three different occasions in quadruplicate. Briefly, organisms were grown for 24 h at 37°C on Sabouraud dextrose agar plates, and saline-washed suspensions of each isolate were used to prepare 3 x 10 7 CFU/ml inocula in SDB. Each well of polystyrene microtiter plates (Nunclon; Nalgene) was inoculated with 20 µl of yeast cell suspension and 180 µl of SDB. One-way analysis of variance was used to compare the optical density values from individual biofilms. All tests were 2-sided. The significance level was set at P < 0.05. (Figure 1 ), whereas the proportion of candidemia cases due to biofilmproducing isolates increased from 19% to 47% for non-C. albicans Candida species and remained fairly constant (17% to 20%) for C. albicans ( Figure 2 Eighty (27.2%) of 294 patients studied were infected by biofilm-forming isolates, as assessed by the %T method. Of these, 20 isolates were high-biofilm producers and 60 low-biofilm producers.
A C C E P T E D

Biofilm production by C. albicans was significantly less frequent (22.6%) than that by all other non-C. albicans species (33.3%; P = 0.04). Among the species most commonly isolated from
Candida BSIs (C. albicans, C. parapsilosis, C. tropicalis, and C. glabrata), biofilm production was most frequently observed for isolates of C. tropicalis (71.4%, 20 of 28), followed by C. glabrata rule out the possibility that the varying ability of different Candida species to metabolize tetrazolium salts may account for differences in XTT reduction rates among our isolates, we compared, in preliminary experiments, the XTT activity of 80 randomly selected isolates (from the pool of 294 isolates). Similar values were obtained and no significant difference was noted between the XTT activities of the 80 isolates (data not shown). Therefore, differences seen in the XTT signals from the 294 isolates we tested for biofilm formation were assumed to be a reflection of changes in cell number.
Candida species isolates were all found susceptible in vitro to amphotericin B, flucytosine, caspofungin, and, except for C. glabrata and Candida krusei, to azole antifungal agents. Ten isolates of C. glabrata showed decreased susceptibility to fluconazole and voriconazole (MICs, ≥16 µg/ml and ≥2 µg/ml), respectively. Four isolates were classified as resistant (MICs, ≥64 µg/ml and ≥4 µg/ml) to these drugs and 6 isolates as susceptible-dose dependent (MICs, 16 to 32 µg/ml and 2 µg/ml). The two isolates of C. krusei were resistant to fluconazole and susceptible to voriconazole. Therapy was considered inadequate for 43 patients. Of these, 31 patients received antifungal treatment after 48 h of the time that a positive blood sample for culture was drawn, 6 patients (fluconazole-treated) were infected by either C. krusei or C. glabrata which was found to be resistant to azoles in vitro, and the remaining six patients were never treated.
Univariate and multivariable analyses. From the univariate analysis of risk factors for mortality in patients with candidemia, age (P < 0.001), hospital-acquired candidemia (P = 0.01),
immunosuppressive therapy (P = 0.003), APACHE III score (P < 0.001), presence of CVC (P = 0.003), infection by C. albicans (P = 0.03), biofilm production by overall Candida species (P < 0.001), and inadequate antifungal therapy (P = 0.01) were variables significantly associated with increased mortality. In contrast, infection by C. parapsilosis was associated with decreased mortality (P = 0.007) ( Table 2) . the patients were stratified for severity of illness, patients infected with a biofilm-forming isolate also had a higher risk of mortality than patients infected with a non-biofilm producer for patients with APACHE III scores less than or equal to 15 (n = 50) (66.7% versus 13.6%; P = 0.002) and for patients with APACHE III scores greater than 15 (n = 244) (70.3% versus 54.1%; P = 0.01). The relationship between biofilm positivity of Candida species isolates and mortality for the 294 patients with candidemia is displayed in Table 3 . Among infections by biofilm-producing isolates, only those due to C. albicans (P < 0.001) or C. parapsilosis (P = 0.003) correlated with increased mortality. No statistically significant differences in mortality between patients infected by biofilmforming isolates and patients infected by biofilm-negative isolates were noted for the other Candida species. When mortality was analyzed in relation to the amount of biofilm produced by overall
Candida species isolates, we found that mortality was lowest if isolates were non-biofilm producers (45.8%) and significantly increased to 66.6% (P = 0.009) and 75% (P = 0.002) if isolates exhibited a low and high biofilm-forming ability, respectively. 
DISCUSSION
Candida species are now the fourth most common cause of nosocomial BSIs worldwide (30).
Variables such as patient age, underlying disease, location in hospital, and antifungal drug exposure may influence the frequency and rank order of Candida species causing BSI (28). In this study, the distribution of Candida species was similar to reports from other European countries (1, 36, 38) , with C. albicans being the fungal species most frequently isolated from blood but significant increases found in the prevalence of non-C. albicans Candida species invading the bloodstream. An exception is the frequency of C. glabrata, which was the fourth most common species in our study but the second most common in Switzerland (22), the United Kingdom (15) and the United States (9). A similar trend was observed in our study for BSI isolates of biofilm-forming non-C. albicans Candida species, whose frequency increased compared to biofilm-forming C. albicans isolates. The explanation for this observation is not clear and warrants further study, but it is possible that some medical procedures might consistently impact the risk of developing candidemia caused by a fungal isolate capable of forming biofilm over the years.
Candidemia ranks among the infections with highest mortality rates (10) . Estimated rates of crude mortality due to candidemia can reach almost 60%, and attributable mortality rates of 49% have been reported in patients with candidemia (8). Candidemia has been associated with mortality rate increases of 10% and 14.5% in hospitalized pediatric and adult patients, respectively (41) . The impact of candidemia on mortality suggested a compelling need for clinical prediction rules to identify subsets of hospitalized patients at particularly high risk for candidemia. In accord with these findings, a high mortality rate (52.3%) was also seen in our patient population.
In the multivariable analysis of factors that may influence clinical outcome, we found, not surprisingly, that inadequate antifungal therapy was an independent predictor of mortality. Previous studies have shown that early and appropriate antifungal treatment correlated with improved candidemia outcomes (1, 6) . Antifungal resistance was rarely found in our study and was restricted to a few isolates. With the exception of C. krusei, 15% of our C. glabrata isolates were resistant to Candida species in that study, though, underscored the need for a larger clinical study.
A C C E P T E D
Candida species and strain type were shown to affect biofilm formation in vitro (3, 11, 19, 37) .
Hawser and Douglas (11) demonstrated that isolates of C. parapsilosis, Candida pseudotropicalis,
and C. glabrata made significantly less biofilm than C. albicans, which is more pathogenic. The finding that C. albicans isolates consistently produce more biofilm in vitro than non-C. albicans isolates was confirmed recently (19). On the other hand, non-C. albicans Candida species, particularly C. tropicalis and C. parapsilosis, appear to form biofilms readily when grown in SDB medium containing 8% glucose (considered very similar to the in vivo milieu) (37) . This capability Another remarkable finding of our study was the association between biofilm-forming ability of C.
A C C E P T E D
albicans and C. parapsilosis isolates and increased mortality rates for patients with BSI due to these organisms, thus suggesting that the capability to form biofilms may be important in contributing to the virulence of C. albicans or enhancing the pathogenic potential of C. parapsilosis. However, Hawser and Douglas (11) In this study, we used polystyrene plates to grow biofilms. Although a valid assay for biofilm formation in C. albicans based on polystyrene microtiter plates has now been established and standardized (33) , it is possible that use of other materials, such those used for indwelling devices including catheters (e.g. silicone elastomer), may give results different from those we obtained here, perhaps because the polystyrene may not reflect exactly the in vivo biofilm formation abilities. In
on November 13, 2017 by guest http://jcm.asm.org/ Downloaded from addition to the substrate material, it is important to note that other environmental parameters, such as substrate preconditioning solutions (i.e., those mimicking physiologic conditions, such as the presence of serum or saliva) and growth media can affect biofilm production. Again, our biofilm assays did not include an initial step, where nonadherent cells are removed after 90 min incubation with the standardized Candida suspension (adhesion phase) and adherent cells are incubated for prolonged period in the presence of media (biofilm formation phase). This step would hamper the co-adhesion of planktonic cells to adherent cells and ensure uniform biofilm formation on plastic surfaces (19). In this context, our study has some limitations. However, our analyses showed that the amount of biofilm formation was highly correlated between the two methods we employed to indirectly measure it. This correlation suggested that varying ability exhibited by our Candida strains to adhere and grow on polystyrene surfaces was really a reflection of intrinsic physiological differences among the various clinical isolates being compared.
In conclusion, we showed that, together with inadequate antifungal therapy and high APACHE III scores, Candida biofilms adversely affect the health of hospitalized patients with candidemia and are thus a significant predictor of mortality. Our findings provide a foundation for future studies examining the correlation between biofilm formation and clinical outcome in high-risk patient populations. e As assessed by %T and XTT absorbance determinations (see Materials and Methods for details). 
